We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Alliance to Study Links Between Genes and Disease

By Biotechdaily staff writers
Posted on 19 Aug 2002
A strategic alliance pairs researchers at the Emory University School of Medicine (Atlanta, GA, USA) with a genomics company in Iceland that has accumulated comprehensive population data to identify genetic factors underlying common diseases. More...
That company is deCode Genetics (Reykjavik).

Decode has created an extensive database that anonymously cross-references genealogic information about the Icelandic population with genetic and disease data from volunteer patients and their relatives in more than 50 disease categories. Emory doctors and scientists will use these genetic clues, along with deCode's genotyping capabilities to advance clinical and laboratory research within the Emory patient population. In addition, Emory will collaborate with deCode on research projects covering many diseases and will contribute clinical and research expertise in a number of medical specialties.

Using large-scale genotyping, deCode scientists are generating genetic fingerprints of each chromosome of the volunteer participants in order to identify small segments of chromosomes shared by patients with a particular disease. Genotypes are compared between closely and distantly related disease sufferers. This enables researchers to identify the particular genes or sections of genes linked to that disease. Armed with these clues, Emory scientists will conduct their own studies among Emory's diverse group of patients to discover the full range of mutations or versions of these genes that might predispose to disease.

"Working with deCode, we can use the genetic clues from the relatively homogeneous Icelandic population to determine whether implicated genes confer disease risk in more complex populations,” said Allan Levey, M.D., Ph.D., Emory neurologist and director of the Emory Center for Neurodegenerative Diseases.





Related Links:
deCode
Emory

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.